Increased Plasma DOPA Decarboxylase Levels in Lewy Body Disorders Are Driven by Dopaminergic Treatment

DOPA Decarboxylase (DDC) has been proposed as a cerebrospinal fluid (CSF) biomarker with increased concentrations in Lewy body disorders (LBDs) and highest levels in patients receiving dopaminergic treatment. Here we evaluate plasma DDC, measured by proximity extension assay, and the effect of dopaminergic treatment in three independent LBD (with a focus on dementia with Lewy bodies (DLB) and Parkinson's disease (PD)) cohorts: an autopsy-confirmed cohort (n = 71), a large multicenter, cross-dementia cohort (n = 1498) and a longitudinal cohort with detailed treatment information (n = 66, median follow-up time[IQR] = 4[4, 4] years). Plasma DDC was not altered between different LBDs and other disease groups or controls in absence of treatment. DDC levels increased over time in PD, being significantly associated to higher dosages of dopaminergic treatment. This emphasizes the need to consider treatment effect when analyzing plasma DDC, and suggests that plasma DDC, in contrast to CSF DDC, is of limited use as a diagnostic biomarker for LBD, but could be valuable for treatment monitoring.

References

Albert M, DeKosky S, Dickson D, Dubois B, Feldman H, Fox N . The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7(3):270-9. PMC: 3312027. DOI: 10.1016/j.jalz.2011.03.008. View

Garo-Pascual M, Gaser C, Zhang L, Tohka J, Medina M, Strange B . Brain structure and phenotypic profile of superagers compared with age-matched older adults: a longitudinal analysis from the Vallecas Project. Lancet Healthy Longev. 2023; 4(8):e374-e385. PMC: 10397152. DOI: 10.1016/S2666-7568(23)00079-X. View

Lees A . The on-off phenomenon. J Neurol Neurosurg Psychiatry. 1989; Suppl:29-37. PMC: 1033307. DOI: 10.1136/jnnp.52.suppl.29. View

Fowler C, Rainey-Smith S, Bird S, Bomke J, Bourgeat P, Brown B . Fifteen Years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study: Progress and Observations from 2,359 Older Adults Spanning the Spectrum from Cognitive Normality to Alzheimer's Disease. J Alzheimers Dis Rep. 2021; 5(1):443-468. PMC: 8293663. DOI: 10.3233/ADR-210005. View

Mappouras D, Stiakakis J, Fragoulis E . Purification and characterization of L-dopa decarboxylase from human kidney. Mol Cell Biochem. 1990; 94(2):147-56. DOI: 10.1007/BF00214121. View

Postuma R, Berg D, Stern M, Poewe W, Olanow C, Oertel W . MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015; 30(12):1591-601. DOI: 10.1002/mds.26424. View

McKeith I, Ferman T, Thomas A, Blanc F, Boeve B, Fujishiro H . Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology. 2020; 94(17):743-755. PMC: 7274845. DOI: 10.1212/WNL.0000000000009323. View

Ortega-Cruz D, Uceda-Heras A, Iglesias J, Zea-Sevilla M, Strange B, Rabano A . A novel histological staging of hippocampal sclerosis that is evident in gray matter loss in vivo. Alzheimers Dement. 2023; 19(7):3028-3040. PMC: 10363577. DOI: 10.1002/alz.12942. View

Pereira J, Kumar A, Hall S, Palmqvist S, Stomrud E, Bali D . DOPA decarboxylase is an emerging biomarker for Parkinsonian disorders including preclinical Lewy body disease. Nat Aging. 2023; 3(10):1201-1209. PMC: 10570139. DOI: 10.1038/s43587-023-00478-y. View

10.

Appleton E, Khosousi S, Ta M, Nalls M, Singleton A, Sturchio A . DOPA-decarboxylase is elevated in CSF, but not plasma, in prodromal and de novo Parkinson's disease. Transl Neurodegener. 2024; 13(1):31. PMC: 11165760. DOI: 10.1186/s40035-024-00421-0. View

11.

. The Parkinson Progression Marker Initiative (PPMI). Prog Neurobiol. 2011; 95(4):629-35. PMC: 9014725. DOI: 10.1016/j.pneurobio.2011.09.005. View

12.

Goldman J, Goetz C, Brandabur M, Sanfilippo M, Stebbins G . Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies. Mov Disord. 2008; 23(15):2248-50. DOI: 10.1002/mds.22322. View

13.

McKhann G, Knopman D, Chertkow H, Hyman B, Jack Jr C, Kawas C . The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7(3):263-9. PMC: 3312024. DOI: 10.1016/j.jalz.2011.03.005. View

14.

McKeith I, Boeve B, Dickson D, Halliday G, Taylor J, Weintraub D . Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017; 89(1):88-100. PMC: 5496518. DOI: 10.1212/WNL.0000000000004058. View

15.

van Rumund A, Pavelka L, Esselink R, Geurtz B, Wevers R, Mollenhauer B . Peripheral decarboxylase inhibitors paradoxically induce aromatic L-amino acid decarboxylase. NPJ Parkinsons Dis. 2021; 7(1):29. PMC: 7979935. DOI: 10.1038/s41531-021-00172-z. View

16.

Paslawski W, Khosousi S, Hertz E, Markaki I, Boxer A, Svenningsson P . Large-scale proximity extension assay reveals CSF midkine and DOPA decarboxylase as supportive diagnostic biomarkers for Parkinson's disease. Transl Neurodegener. 2023; 12(1):42. PMC: 10476347. DOI: 10.1186/s40035-023-00374-w. View

17.

Barker M, Gottesman R, Manoochehri M, Chapman S, Appleby B, Brushaber D . Proposed research criteria for prodromal behavioural variant frontotemporal dementia. Brain. 2022; 145(3):1079-1097. PMC: 9050566. DOI: 10.1093/brain/awab365. View

18.

Assarsson E, Lundberg M, Holmquist G, Bjorkesten J, Thorsen S, Ekman D . Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS One. 2014; 9(4):e95192. PMC: 3995906. DOI: 10.1371/journal.pone.0095192. View

19.

Foguem C, Manckoundia P . Lewy Body Disease: Clinical and Pathological "Overlap Syndrome" Between Synucleinopathies (Parkinson Disease) and Tauopathies (Alzheimer Disease). Curr Neurol Neurosci Rep. 2018; 18(5):24. DOI: 10.1007/s11910-018-0835-5. View

20.

van der Flier W, Scheltens P . Amsterdam Dementia Cohort: Performing Research to Optimize Care. J Alzheimers Dis. 2018; 62(3):1091-1111. PMC: 5870023. DOI: 10.3233/JAD-170850. View